Synovus Financial’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $101K | Hold |
48,000
| – | – | ﹤0.01% | 899 |
|
|
2025
Q1 | $58.6K | Hold |
48,000
| – | – | ﹤0.01% | 886 |
|
|
2024
Q4 | $61.9K | Hold |
48,000
| – | – | ﹤0.01% | 862 |
|
|
2024
Q3 | $132K | Hold |
48,000
| – | – | ﹤0.01% | 890 |
|
|
2024
Q2 | $108K | Hold |
48,000
| – | – | ﹤0.01% | 828 |
|
|
2024
Q1 | $115K | Hold |
48,000
| – | – | ﹤0.01% | 830 |
|
|
2023
Q4 | $79.7K | Hold |
48,000
| – | – | ﹤0.01% | 811 |
|
|
2023
Q3 | $92.2K | Hold |
48,000
| – | – | ﹤0.01% | 823 |
|
|
2023
Q2 | $69.1K | Hold |
48,000
| – | – | ﹤0.01% | 827 |
|
|
2023
Q1 | $101K | Hold |
48,000
| – | – | ﹤0.01% | 810 |
|
|
2022
Q4 | $54.2K | Hold |
48,000
| – | – | ﹤0.01% | 845 |
|
|
2022
Q3 | $78K | Hold |
48,000
| – | – | ﹤0.01% | 828 |
|
|
2022
Q2 | $63K | Hold |
48,000
| – | – | ﹤0.01% | 829 |
|
|
2022
Q1 | $77K | Hold |
48,000
| – | – | ﹤0.01% | 834 |
|
|
2021
Q4 | $99K | Buy |
+48,000
| New | +$99K | ﹤0.01% | 845 |
|